Related Experiment Videos
[Clinical studies of 9,3"-diacetylmidecamycin in pediatric field (author's transl)]
Insights
9,3"-diacetylmidecamycin (MOM) is a new macrolide antibiotic effective for pediatric respiratory infections. Clinical trials showed a 56.5% efficacy rate with minimal side effects, indicating its usefulness.
Area of Science:
- Pharmacology
- Pediatric Infectious Diseases
- Microbiology
Background:
- Macrolide antibiotics are crucial for treating bacterial infections.
- New macrolide compounds are continuously investigated for improved efficacy and safety profiles.
- Pediatric respiratory tract infections pose a significant public health challenge.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of 9,3"-diacetylmidecamycin (MOM) in pediatric patients.
- To determine the effectiveness of MOM in treating various respiratory tract infections.
- To assess the tolerability and side effect profile of MOM in children.
Main Methods:
- A clinical trial involving 46 pediatric patients aged 1 month to 11 years.
- Patients diagnosed with acute pharyngitis, tonsillitis, bronchitis, pneumonia, and pertussis were enrolled.
- MOM was administered orally at a daily dose of 20-40 mg/kg, divided into three doses.
Main Results:
- An overall efficacy rate of 56.5% was observed.
- Excellent or good clinical results were achieved in 26 out of 46 patients.
- Side effects were reported in 4 patients, including diarrhea, exanthema, urticaria, and eosinophilia.
Conclusions:
- 9,3"-diacetylmidecamycin (MOM) demonstrates utility as an oral antibiotic for pediatric bacterial infections.
- MOM is particularly effective for respiratory tract infections, including those caused by Mycoplasma pneumoniae.
- The antibiotic is well-tolerated and easy to administer to pediatric patients.
Abstract:
Clinical trials of 9,3"-diacetylmidecamycin (MOM), a new macrolide antibiotic were carried out on 46 pediatric patients of 1 month to 11 years old with infections (acute pharyngitis 12, acute tonsillitis 1, acute bronchitis 14, asthmatic bronchitis 10, acute pneumonia 1, primary atypical pneumonia 2, Mycoplasma pneumonia 4 and pertussis 2). As a rule, MOM was given orally at a daily dose of 20 approximately 40 mg/kg divided into 3 times. The clinical results were excellent in 5 patients, good in 21, fair in 7 and poor in 13 and the efficacy rate was 56.5%. Side effects were observed in 4 patients (diarrhea, exanthema, urticaria and eosinophilia, 1 patient respectively). MOM is easy to take and a useful antibiotic for treating patients with bacterial infections, in particular, respiratory tract infection caused by Mycoplasma pneumoniae.